Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA Chief Favors LDT Approach In Bucshon-DeGette Bill

Executive Summary

FDA Commissioner Scott Gottlieb told Reps. Larry Bucshon, R-Ind. and Diana DeGette, D-Colo., that he favors their approach to regulating laboratory developed tests, as spelled out in their draft Diagnostics Accuracy and Innovation Act bill released last spring. The traditional device approval process is a "poor fit" for LDTs, he added.


Related Content

FDA Pathway Options Are Growing For Diagnostics, FDA's Gottlieb Tells Commercial Labs
HHS Chief Scores With Congress On DME Bid Program, Telehealth Pay, But Says LDTs Complex
New HHS Chief Alex Azar Supports LDT Regulation, Cost-Saving Bundles
Medtech's Unfinished Business For Congress In 2018: What's Ahead
A New York Minute: US FDA Leverages State's Health Department To Expedite NGS Reviews
Q&A Exclusive: FDA Commissioner Talks About His Tenure, Recruiting And LDTs
Lab Professionals Oppose Draft Dx Reform Bill; Lab, IVD Industry Ready To Work With Congress
Diagnostics Reg Overhaul Floated In US House
FDA Passes The Buck On LDTs, But Floats Ideas





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts